Saxenda, Victoza · Evidence-based safety and harm-reduction overview.
| Also known as | Saxenda, Victoza |
| Category | GLP-1 |
| fda_approval | Victoza approved 2010 for diabetes; Saxenda approved 2014 for weight management |
| mechanism_class | Human GLP-1 receptor agonist with fatty-acid modification |
| route | Subcutaneous injection (once daily) |
| half_life | approximately 13 hours; allows once-daily dosing |
| cost_note | Prescription medications; typically require insurance coverage or significant out-of-pocket cost |
| US legal status | Liraglutide is an FDA-approved prescription medication, marketed as Saxenda for chronic weight management in adults and Victoza for type 2 diabetes. It is prescription-only and must be obtained through a licensed clinician and pharmacy; sourcing unbranded research or compounded liraglutide outside that system is unsafe and not lawful for human use. |
Liraglutide is a once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist, also classified as an incretin mimetic, that slows gastric emptying, enhances glucose-dependent insulin secretion, and acts on appetite and satiety centers in the brain. It is an established, regulated medication used under medical supervision for type 2 diabetes and chronic weight management.
Liraglutide is a human GLP-1 receptor agonist, a 31-amino-acid analog of native GLP-1 modified with a 16-carbon fatty acid side chain that increases binding to albumin and extends half-life. It activates GLP-1 receptors on pancreatic beta cells (enhancing glucose-dependent insulin secretion), alpha cells (inhibiting glucagon when blood glucose is elevated), neurons in the hypothalamus and brainstem (promoting satiety), and possibly on enteric and other tissues.
Liraglutide was developed by Novo Nordisk as a long-acting human GLP-1 analog with a fatty-acid modification for improved stability and once-daily dosing. Victoza was FDA-approved for type 2 diabetes in 2010, and Saxenda was approved for chronic weight management in 2014, based on large randomized controlled trials demonstrating efficacy and safety in each indication.
Research and large, published clinical trials show liraglutide improves glycemic control (HbA1c reduction) in type 2 diabetes and produces clinically meaningful weight loss at approved doses of 1.8 and 3.0 mg daily, which underpins its FDA approvals for Victoza and Saxenda respectively. Studies including cardiovascular outcome trials report cardiovascular benefits in some patient populations, while also thoroughly documenting the side-effect and risk profile common to the GLP-1 receptor agonist class.
In clinical trials, liraglutide for weight management (Saxenda) was administered as a daily subcutaneous injection starting at 0.6 mg and escalating by 0.6 mg weekly until the maintenance dose of 3.0 mg daily was reached. For diabetes (Victoza), the maintenance dose is typically 1.8 mg daily, and doses exceeding 1.8 mg are not approved for diabetes.
This is general research/context information, not medical advice or a recommended protocol.
Combining liraglutide with other GLP-1 agonists or incretin-based therapies is not recommended and is not studied; a single GLP-1 or dual GIP/GLP-1 agent (like tirzepatide) is the standard approach when additional pharmacotherapy is needed.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsBoth contain liraglutide but are approved for different uses and dose ranges: Saxenda is approved for chronic weight management in adults with obesity or overweight status with weight-related comorbidities, at a maximum dose of 3.0 mg daily. Victoza is approved for type 2 diabetes at a dose up to 1.8 mg daily. A clinician determines which product and indication apply to your situation.
We do not provide dosing advice. Liraglutide is a prescription medicine with a structured dose-escalation schedule starting at 0.6 mg weekly for four weeks, then increasing by 0.6 mg weekly. Your prescribing clinician must set and adjust your dose based on your tolerance, response, and medical status.
Rodent studies showed an increase in thyroid C-cell tumors with GLP-1 agonists at high doses, leading to an FDA boxed warning. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), though human risk remains unclear.
Yes, if your clinician determines you have both type 2 diabetes and are overweight or obese; Victoza provides diabetes control and modest weight loss. However, Saxenda is the weight-management-specific product and may be preferred for standalone weight management without diabetes.
Nausea is very common, especially during dose escalation, and typically improves over time. Gastrointestinal effects (vomiting, diarrhea, constipation) are also frequent. Modest increases in heart rate and injection-site reactions are reported. Discuss expected side effects and management strategies with your clinician.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.